Navigation Links
PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
Date:5/30/2013

SCHOFIELD, Wis., May 30, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.

Highlights of the almost seven-minute interview, include:

  • Revenue Potential for LipiGesic® M Could Exceed $50 Million
  • Expanding Retail Chain-Store Distribution
  • Expansion into International Markets
  • Potential Patent Portfolio Acquisition Worth Millions
  • Market Capitalization Currently under $1 Million

Revenue Potential
Russ Mitchell , the Chairman and CEO of PuraMed BioScience, commented that with nearly 60 million Americans suffering from migraines the revenue potential for LipiGesic M, their over-the-counter migraine pain relief product, could generate over $50 million in sales annually by capturing just 1 percent of the migraine market.

Mr. Mitchell also discussed expanding distribution for their over-the-counter migraine pain reliever product, LipiGesic M, which is currently available in approximately 15,000 Walgreen's and CVS/pharmacy stores in all 50 states in the United States. According to Mr.Mitchell, he expects LipiGesic M to expand distribution into additional chains and wholesalers including all major retailers known to carry health and beauty products.

Off air, Mr. Mitchell said, "This expanded distribution would include mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains, which would add approximately another 21,000 stores."

In addition to US distribution, PuraMed BioScience has received its initial order from Columbia and has plans to expand to other Latin American countries as well as other regions around the world.

Patent Portfolio Acquisition
In the interview, Mr. Mitchell discussed current negotiations to acquire a patent portfolio of products in the anti-inflammatory, anti-bacterial, and anti-viral categories. Upon completion of the acquisition, PuraMed BioScience intends to license some of these patents to larger key manufacturers or bring these products to market directly. Mr. Mitchell commented, "Each one of those categories is huge, and has the potential to bring in many millions of dollars of additional revenue as these products get placed into the market."

To access the online interview please visit http://www.wallstreetnewscast.com/profile/pmbs.html

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, www.lipiGesic.com, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Melissa Diaz ,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017   Divoti ... Medical Alert Jewelry up to the standard of the latest FDA ... (Launched: June 2017). Anyone in need of Medical ID ... Divoti Medical Alert Jewelry are engraved in terms of the ... ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
Breaking Medicine News(10 mins):